AI Article Synopsis
Article Abstract
We studied the cardioprotective effect of anti-ischemic drug trimetazidine in the thrombolytic therapy of acute myocardial infarction. Trimetazidine (60 mg/day) effectively inhibits lipid peroxidation and moderates reperfusion damage to the myocardium assessed by ECG, QRS index of damaged heart, and release of creatine phosphokinase into circulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1022961112062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Am J Emerg Med
November 2017
Department of Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Electronic address:
Purpose: Trimetazidine (TMZ) improves clinical outcomes in patients with chronic heart failure and stable coronary artery disease. No study has yet evaluated the efficacy of TMZ in type 2 diabetes patients with acute myocardial infarction (AMI) undergoing Percutaneous Coronary Intervention (PCI). We performed this study to evaluate the efficacy TMZ in DM patients with AMI undergoing PCI, such as the effect on reductions in myocardial enzyme, improvements in liver function, modulation of glucose levels, and improvement in cardiac function.
View Article and Find Full Text PDFIt is of great therapeutic significance that disordered function of the vascular endothelium which supply the affected ocular structures plays a major role in the pathogenesis and development of age-related macular degeneration. Chronic inflammation is closely linked to diseases associated with endothelial dysfunction, and age-related macular degeneration is accompanied by a general inflammatory response. According to current concept, age-related macular degeneration is a local manifestation of systemic vascular disease.
View Article and Find Full Text PDFCardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.
Cardiol Res
April 2014
Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Email:
Background: Trimetazidine is an anti-ischemic agent with anti-oxidant activity. This study sought to evaluate the impact of oral trimetazidine on extent of myocardial damage in diabetic patients who were presented with anterior wall ST-segment elevation myocardial infarction (STEMI).
Methods: One hundred patients were prospectively enrolled, and then randomly assigned to receive oral trimetazidine (70 mg then 35mg bid) (group A, 50 patients) or placebo (group B, 50 patients), starting before thrombolysis.
Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry.
Clin Res Cardiol
December 2013
Division of Cardiology, Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, 626-770, Korea.
Background: Excess myocardial fatty acid oxidation can cause a range of deleterious myocardial effects. Trimetazidine (TMZ) is a clinically effective antianginal agent that selectively inhibits long-chain 3-ketoacyl CoA thiolase, reducing fatty acid oxidation and stimulating glucose oxidation. The role of TMZ in acute myocardial infarction (AMI), however, remains unclear.
View Article and Find Full Text PDFPharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control.
Cochrane Database Syst Rev
October 2009
University Department of Surgery, Royal Free Hospital and University College School of Medicine, 9th Floor, Royal Free Hospital, Pond Street, London, UK, NW3 2QG.
Background: Vascular occlusion to reduce blood loss is used during elective liver resection but results in significant ischaemia reperfusion injury. This, in turn, might lead to significant postoperative liver dysfunction and morbidity. Various pharmacological drugs have been used with an intention to ameliorate the ischaemia reperfusion injury in liver resections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!